Saturday, October 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutideobesityadipose inflammationpreclinical

Mouse study finds semaglutide's adipose anti-inflammatory effect reverses after withdrawal

Visceral fat macrophage infiltration and hepatic steatosis returned to obese-control levels during regain, though fasting glucose and insulin stayed partly improved.

PR
By Priya Raman · Science Reporter

The wire

  1. 01Diet-induced obese male C57BL/6 mice got semaglutide 60 nmol/kg intraperitoneally every three days for three weeks, then drug withdrawal on continued high-fat diet, reported in Endocrinology and Metabolism.
  2. 02Treatment cut pro-inflammatory macrophages, crown-like structures and inflammatory gene expression in visceral fat, with subcutaneous fat minimally affected; all reverted after stopping.
  3. 03This is a rodent weight-cycling model, not human data, and does not establish what happens to patients who discontinue semaglutide.

From the source

Transient Adipose Inflammatory Remodeling during High-Dose Semaglutide-Induced Weight Loss and Regain

Endocrinology and metabolism (Seoul, Korea) · 2026 Oct 22 · Seo M, Julietta V, Averia M et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →